Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.…
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Cullinan Therapeutics (NASDAQ: CGEM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 109 employees.
The shares were at 8.890 USD on 20 November 2026, up 23.6% over 52 weeks. Its 52-week range is 7.250 USD to 23.19 USD: the price is 61.7% below the high and 22.6% above the low.
Its market capitalisation is 577.15M USD.
Cullinan Therapeutics reports return on equity of -53.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 287.57M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 34.70 USD is 290.3% above the current price. The next earnings report is expected on 11 March 2027.